Publications by authors named "Zongli Zhou"
Article Synopsis
- - Agonists targeting M1 muscarinic acetylcholine receptors show potential for treating Alzheimer's disease, with xanomeline as a main example, although it has notable side effects.
- - EUK1001, a modified version of xanomeline, has been effective in reducing neurodegenerative symptoms in mice lacking β-amyloid pathology, suggesting it could be a promising alternative.
- - In tests, EUK1001 improved cognitive performance in AD model mice and reduced specific amyloid levels, indicating it may work by modifying amyloid precursor protein processing and potentially serve as a viable Alzheimer's treatment.
Butyrate-induced GPR41 activation inhibits histone acetylation and cell growth.
J Genet Genomics
August 2012
Butyrate has been recently identified as a natural ligand of the G-protein-coupled receptor 41 (GPR41). In addition, it is an inhibitor of histone deacetylase (HDAC). Butyrate treatment results in the hyperacetylation of histones, with resultant multiple biological effects including inhibition of proliferation, induction of cell cycle arrest, and apoptosis, in a variety of cultured mammalian cells.
View Article and Find Full Text PDF[Compliance of the patients and related influential factors on the topical antifungal treatment of onychomycosis].
Zhonghua Liu Xing Bing Xue Za Zhi
July 2011
Objective: To explore the compliance rate of patients and its influential factors on topical antifungal treatment of onychomycosis.
Methods: Dermatology life quality index (DLQI) and self-administered questionnaires were employed in this study.
Results: The overall compliance rate of the topical antifungal treatment was 23.
[Inhibitory effects of mizolastine on substance P-induced production of leukotriene B4 and interleukin 5 in mouse skin].
Zhejiang Da Xue Xue Bao Yi Xue Ban
March 2006
Objective: To observe the inhibitory effect of mizolastine on substance P(SP)-induced production of leukotriene B(4) (LTB(4)) and interleukin 5 (IL-5) in mouse skin.
Methods: Mice were fed with different doses of mizolastine or other control drugs, 30 min after administration animals were injected intradermally with SP on the back. The treated skin samples were taken and competitive enzyme-link immunoassay (ELISA) method was applied to detect LTB (4) and IL-5 in the skin samples.